Abstract:AIM:Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as potent drug development target for treating diabetes and obesity. Here, we designed and evaluated novel long-acting GLP-1R G protein biased agonist with potent clinical application. MAIN METHODS:GLP-1R G-protein biased sequences were screened via a high-throughput autocrine-based strategy and then fused to Exendin (9-39). These fusion peptides were further performed with site-specific modification. Surface plasmon resonance (SPR) measurements, GLP-1R activation potencies and plasma stability tests were applied to screen optimal candidate. Acute and chronic hypoglycemic and insulinotropic activities of selected agent were evaluated in diabetic and obese rodent animals. MAIN FINDINGS:AX09 exert highest binding affinities for GLP-1R extracellular domain (GLP-1R ECD). Further in vitro plasma stability and GLP-1R activation assays demonstrated better potency of AX18. Acute pharmacodynamic evaluation of AX18 demonstrated the promising insulinotropic and hypoglycemic activities which were exhibited in a dose-dependent manner. Prolonged hypoglycemic efficacies of AX18 were also observed in both hypoglycemic duration test and multiple oral glucose tolerance tests (OGTTs) in the diabetic mice. Further pharmacokinetic test in cynomolgus monkeys exhibited that the half-life of AX18 was more than 6 days. Once weekly treatment of AX18 in diabetic mice for 8-week achieved significantly improved %HbA1C, insulin resistance, glucose tolerance, β-cells and diabetic retinal injury. Chronic treatment of AX18 in diet-induced obese (DIO) mice also exhibited beneficial efficacies on %HbA1C, inflammation-related factors lowering, and weight gains. CONCLUSION:AX18, as a novel GLP-1R G protein biased agonist, exhibited potency for treating diabetes mellitus and its complications.

Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist

Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue

Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.

Engineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic

A novel GLP-1 analog, a dimer of GLP-1 via covalent linkage by a lysine, prolongs the action of GLP-1 in the treatment of type 2 diabetes

Prolonged Activation of the GLP-1 Receptor via Covalent Capture

Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides

Potent and Protease Resistant Azapeptide Agonists of the GLP‐1 and GIP Receptors

A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis.

Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-like Peptide-1 Conjugates.

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

Α/sulfono-Γ-aapeptide Hybrid Analogues of Glucagon with Enhanced Stability and Prolonged in Vivo Activity

Nanoparticles induced by embedding self-assembling cassette into glucagon-like peptide 1 for improving in vivo stability.

High cell density cultivation of recombinant Escherichia coli for prodrug of recombinant human GLPs production

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

Binding sites and design strategies for small molecule GLP-1R agonists

Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839